Medtronic has just announced the results of the RESOLUTE All Comers study, which compared the performance of its Resolute drug eluting stent to that of Abbott‘s XIENCE V. The results, which were announced at the ongoing 2010 EuroPCR meeting in Paris, show that the Resolute stent matches XIENCE V in both safety and efficacy. While the Resolute stent is currently approved for sale in Europe, the stent is still classified as an investigational device in the US.
More details about the study from the press release:
At one year, the Resolute DES was shown to be as effective as the Xience DES in reducing the need for repeat procedures, and both second-generation stents were associated with low and similar rates of death from cardiac causes and heart attacks attributed to the treated vessel.
The primary endpoint of the study was target lesion failure (TLF) – a composite of cardiac death, target vessel myocardial infarction and clinically driven target lesion revascularization. The Resolute DES posted TLF rates of 8.2 percent versus 8.3 percent for the Xience DES (non-inferiority p=<0.001).
Press release: Medtronic’s Resolute® Drug-Eluting Stent Matches Market-Leading Rival in Large Head-to-Head Study…
Flashbacks: Medtronic Improves Its Driver Bare-Metal Stent System; Abbott XIENCE V Drug Eluting Stent Outperforms Boston Scientific’s TAXUS Express2 in Trial; FDA Approves Abbott’s Everolimus Eluting Stent; New Xience Abbot Stent Gets EU OK